Q-omics provides the consensus-scored DBF4B profile across patient tissues and cancer cell-line models. DBF4B expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DBF4B is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, DBF4B RNA expression shows 21,439 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where DBF4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DBF4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DBF4B survival associations across molecular data types. DBF4B RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DBF4B RNA expression–survival associations across cancer types. High DBF4B expression shows unfavorable associations in ACC, KIRC, KICH, LIHC, MESO and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DBF4B RNA expression.
This table summarizes DBF4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DBF4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DBF4B shows higher tumor expression in HNSC, COAD, BLCA, LUAD, STAD and LIHC. The HNSC box plot shows higher DBF4B RNA expression in tumor versus normal tissue (log2 FC = +1.264, t-test p < 0.001).
This table shows molecular features associated with DBF4B in patient tissues and cancer cell lines. In patient samples, DBF4B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DBF4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
